StoneX Group’s Cue Biopharma CUE Stock Holding History

StoneX Group’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-469	Closed	-$12.8K	–	902
2025 Q1	$12.8K	Buy	+469	New	+$17.4K	﹤0.01%	818

Other funds holding CUE

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

GWMR

GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

StoneX Group's CUE Position: Q2 2025 in Review

StoneX Group sold out of Cue Biopharma (CUE) in Q2 2025, closing a stake of 469 shares — an estimated $12.8K sold.

StoneX Group first reported a position in CUE in Q1 2025 and held it in 1 quarter. The position peaked at $12.8K in Q1 2025. 47 funds tracked by Wall St. Rank hold CUE as of Q2 2025.

StoneX Group reported no remaining Cue Biopharma position as of Q2 2025 after selling out during the quarter.
StoneX Group sold 469 Cue Biopharma shares in Q2 2025, an estimated $12.8K.
StoneX Group first reported a position in Cue Biopharma in Q1 2025 and held it in 1 quarter.
StoneX Group's Cue Biopharma position peaked at $12.8K in Q1 2025.
47 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2025.

Based on StoneX Group's 13F filing for Q2 2025, filed 13 Aug 2025.